13.09

1.39% 0.18

After Hours: 13.11 0.02 +0.15%

Atrium Therapeutics Inc (RNA)

Overview News Price History Option Chain Financials Discussions Forecast

Atrium Therapeutics Inc stock is traded at $13.09, with a volume of 213.38K. It is up +1.39% in the last 24 hours and down -4.24% over the past month. Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Previous Close:

$12.91

Open:

$12.94

24h Volume:

213.38K

Relative Volume:

0.14

Market Cap:

$203.09M

Revenue:

$10.73M

Net Income/Loss:

$-455.74M

P/E Ratio:

-5.5116

EPS:

-2.375

Net Cash Flow:

$-502.70M

1W Performance:

+0.77%

1M Performance:

-4.24%

6M Performance:

-81.24%

1Y Performance:

-50.15%

1-Day Range:

$12.80

$13.30

1-Week Range:

$12.71

$13.57

52-Week Range:

$11.95

$73.06

Atrium Therapeutics Inc Stock (RNA) Company Profile

Name

Atrium Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

Address

Employee

391

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

RNA's Discussions on Twitter

Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNA Atrium Therapeutics Inc	13.09	200.30M	10.73M	-455.74M	-502.70M	-2.375
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-26	Initiated	Wells Fargo	Overweight
Sep-17-25	Initiated	Roth Capital	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Bernstein	Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Jun-11-25	Initiated	Raymond James	Strong Buy
Mar-13-25	Initiated	Citigroup	Buy
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-20-24	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Sep-24-24	Initiated	Goldman	Buy
Aug-28-24	Initiated	Barclays	Overweight
May-03-24	Initiated	BofA Securities	Buy
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight
May-22-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Strong Buy
Sep-07-21	Initiated	Evercore ISI	Outperform
Jun-17-21	Initiated	Needham	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Wells Fargo	Overweight

View All

Atrium Therapeutics Inc Stock (RNA) Latest News

May 03, 2026

RNA 260618 33.00P (RNA260618P33000) Stock Options Chain | Quotes & News - Moomoo

May 03, 2026

Apr 29, 2026

Fierce Biotech Fundraising Tracker '26: Vivacta snags $50M+ series A; Coultreon reels in $125M - Fierce Biotech

Apr 29, 2026

Apr 28, 2026

Atrium Therapeutics earns $15M from Bristol Myers Squibb By Investing.com - Investing.com South Africa

Apr 23, 2026

Atrium Therapeutics earns $15M from Bristol Myers Squibb - Investing.com

Apr 23, 2026

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire

Apr 23, 2026

RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 23, 2026

RNA (Atrium Therapeutics Inc.) posts 70.8 percent year over year Q1 2026 revenue growth, shares rise 3.71 percent. - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

Atrium Therapeutics grants RSUs and options to executive | RNA Insider Trading - Stock Titan

Apr 22, 2026

[Form 4] Atrium Therapeutics, Inc. Insider Trading Activity - Stock Titan

Apr 22, 2026

Atrium Therapeutics (RNA) CFO awarded 30,000 RSUs and 60,000 stock options - Stock Titan

Apr 22, 2026

Atrium Therapeutics (RNA) director Gallagher granted RSUs and 205,000-share option - Stock Titan

Apr 22, 2026

Atrium Therapeutics (RNA) CSO awarded 30,000 RSUs and 60,000 options - Stock Titan

Apr 22, 2026

Atrium Therapeutics (RNA) CSO granted RSUs and 60,000 stock options in Form 4 - Stock Titan

Apr 22, 2026

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month - Sahm

Apr 22, 2026

Apr 21, 2026

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network

Apr 21, 2026

Apr 20, 2026

Omdia: India’s smartphone shipments fell 5% in 1Q26 amid channel caution and pricing pressures - Weekly Voice

Apr 20, 2026

Atrium offers stock awards to 7 new hires under Nasdaq rule - Stock Titan

Apr 20, 2026

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Grand Junction Daily Sentinel

Apr 20, 2026

Apr 18, 2026

Form S-8Securities to be offered to employees in employee benefit plans - ADVFN

Apr 18, 2026

Apr 14, 2026

Atrium Therapeutics Inc - Reuters

Apr 14, 2026

Apr 09, 2026

Atrium Therapeutics Inc. Live Share Prices and Trades. RNA.US Live Streaming Share Prices. - London South East

Apr 09, 2026

Is Atrium Therapeutics (RNA) Stock Declining | Price at $13.72, Up 0.15%Mid Cap Momentum - Newser

Apr 09, 2026

Apr 08, 2026

T. Rowe Price holds 1.55M Atrium shares (10.0%) (NASDAQ: RNA) - Stock Titan

Apr 08, 2026

Apr 06, 2026

Is Atrium Therapeutics (RNA) Stock Worth Buying Now | Price at $13.77, Up 2.46%Pro Trader Recommendations - Newser

Apr 06, 2026

Apr 02, 2026

RNA Rallies on Expansion News - Newser

Apr 02, 2026

Apr 01, 2026

Stock List: Research Stocks from Around the World - GuruFocus

Apr 01, 2026

Mar 31, 2026